Company profile
Biofrontera Inc.
NASDAQ:BFRIBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| AMINOLEVULINIC ACID HYDROCHLORIDE | approved | — | 0 | — |
| Benzoyl peroxide | approved | — | 1 | approved |
| Erythromycin | approved | — | 5 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02799030 | phase2 | completed | 2006-10-01 | 2007-03-01 | Biofrontera Bioscience GmbH | A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis |
| NCT02799082 | phase3 | completed | 2007-12-01 | 2008-10-01 | Biofrontera Bioscience GmbH | Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis. |
| NCT02799069 | phase3 | completed | 2008-04-01 | 2009-08-01 | Biofrontera Bioscience GmbH | Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy |
| NCT01966120 | phase3 | completed | 2013-10-01 | 2014-09-01 | Biofrontera Bioscience GmbH | Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT) |
| NCT02144077 | phase3 | completed | 2014-01-28 | 2015-11-17 | Biofrontera Bioscience GmbH | Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 050769 | NDA | BIOFRONTERA INC | ||||
Loading… | ||||||
| NDA 208081 | NDA | BIOFRONTERA INC | ||||
Loading… | ||||||